<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-15.7.1'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//pharminent.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-june-10-2026/</loc>
  <lastmod>2026-06-10T22:46:04Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • June 10, 2026</news:title>
   <news:publication_date>2026-06-10T22:46:01Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/81736-2/</loc>
  <lastmod>2026-06-10T20:42:19Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title></news:title>
   <news:publication_date>2026-06-10T20:42:15Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-june-10-2026/</loc>
  <lastmod>2026-06-10T20:27:20Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Manufacturing Intelligence • Weekly Digest • June 10, 2026</news:title>
   <news:publication_date>2026-06-10T20:27:16Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/strategic-news-watch/strategic-news-watch-june-10-2026/</loc>
  <lastmod>2026-06-10T18:15:41Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Strategic News Watch • June 10, 2026</news:title>
   <news:publication_date>2026-06-10T18:15:36Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/aquipta-recommended-by-nice-for-acute-migraine-treatment/</loc>
  <lastmod>2026-06-10T15:25:19Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Aquipta recommended by NICE for acute migraine treatment</news:title>
   <news:publication_date>2026-06-10T13:35:05Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/astrazenecas-extensive-obesity-drug-push-125m-for-ultrasound-aided-genetic-medicine/</loc>
  <lastmod>2026-06-10T15:25:22Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>AstraZeneca&amp;#039;s &amp;#039;extensive&amp;#039; obesity drug push; $125M for ultrasound-aided genetic medicine</news:title>
   <news:publication_date>2026-06-10T13:12:00Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/oncology/oncology-intelligence-digest-june-9-2026/</loc>
  <lastmod>2026-06-10T13:06:02Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Oncology Intelligence Digest • June 9, 2026</news:title>
   <news:publication_date>2026-06-10T13:05:59Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/lilly-wins-new-fda-approval-for-eczema-drug-ebglyss/</loc>
  <lastmod>2026-06-10T15:25:24Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Lilly wins new FDA approval for eczema drug Ebglyss</news:title>
   <news:publication_date>2026-06-10T12:59:56Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/discs-fda-meeting-sets-clear-path-for-embattled-rare-blood-disease-drug/</loc>
  <lastmod>2026-06-10T15:25:26Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Disc&amp;#039;s FDA meeting sets &amp;#039;clear path&amp;#039; for embattled rare blood disease drug</news:title>
   <news:publication_date>2026-06-10T12:31:25Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/bayers-asundexian-starts-eu-review-for-ischaemic-stroke/</loc>
  <lastmod>2026-06-10T15:25:27Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Bayer&amp;#039;s asundexian starts EU review for ischaemic stroke</news:title>
   <news:publication_date>2026-06-10T12:00:43Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/abbvies-migraine-drug-cleared-for-migraine-attacks-on-nhs/</loc>
  <lastmod>2026-06-10T15:25:29Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>AbbVie&amp;#039;s migraine drug cleared for migraine attacks on NHS</news:title>
   <news:publication_date>2026-06-10T10:51:09Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/aditxt-and-ignite-announce-merger-plans-with-strategic-partner-2/</loc>
  <lastmod>2026-06-10T15:25:30Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Aditxt and Ignite announce merger plans with strategic partner</news:title>
   <news:publication_date>2026-06-10T10:09:36Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/cancer-biotech-parabilis-books-record-ipo-raising-670m/</loc>
  <lastmod>2026-06-10T15:25:31Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Cancer biotech Parabilis books record IPO, raising $670m</news:title>
   <news:publication_date>2026-06-10T09:55:07Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/81733-2/</loc>
  <lastmod>2026-06-10T20:38:51Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title></news:title>
   <news:publication_date>2026-06-09T20:35:38Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/strategic-news-watch/strategic-news-watch-june-9-2026/</loc>
  <lastmod>2026-06-09T19:57:52Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Strategic News Watch • June 9, 2026</news:title>
   <news:publication_date>2026-06-09T19:57:50Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/alzecure-enters-collaboration-and-with-lilly-for-alzheimers-project/</loc>
  <lastmod>2026-06-09T15:55:45Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Alzecure enters collaboration and with Lilly for Alzheimer&amp;#039;s project</news:title>
   <news:publication_date>2026-06-09T13:55:17Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/ada-astrazeneca-hands-structure-a-win-with-relatively-underwhelming-glp-1-pill-data/</loc>
  <lastmod>2026-06-09T15:55:48Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>ADA: AstraZeneca hands Structure a win with &amp;#039;relatively underwhelming&amp;#039; GLP-1 pill data</news:title>
   <news:publication_date>2026-06-09T12:41:15Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/gsk-pays-10-6b-for-cancer-biotech-nuvalent-in-industrys-second-biggest-buy-of-the-year/</loc>
  <lastmod>2026-06-09T15:55:51Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>GSK pays $10.6B for cancer biotech Nuvalent in industry&amp;#039;s second-biggest buy of the year</news:title>
   <news:publication_date>2026-06-09T12:12:19Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/ada-lilly-bests-novo-again-takes-glp-1-pill-foundayo-to-fda-for-diabetes-approval/</loc>
  <lastmod>2026-06-09T15:55:51Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval</news:title>
   <news:publication_date>2026-06-09T11:58:36Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/pfizers-hympavzi-secures-fda-expanded-indications-for-haemophilia-2/</loc>
  <lastmod>2026-06-09T15:55:53Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Pfizer&amp;#039;s Hympavzi secures FDA expanded indications for haemophilia</news:title>
   <news:publication_date>2026-06-09T09:05:26Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
